The effect of human proinsulin C-peptide on erythrocyte deformability in patients with Type I diabetes mellitus

Diabetologia. 1999 Apr;42(4):465-71. doi: 10.1007/s001250051180.

Abstract

Aims/hypothesis: In recent years, evidence has arisen that proinsulin C-peptide exerts biological effects especially on microcirculation, e.g. C-peptide has been shown to increase skin microcirculation in patients with Type I (insulin-dependent) diabetes mellitus and to activate endothelial nitric oxide synthase. This study aimed to investigate the influence of pro-insulin C-peptide on erythrocyte deformability which was assessed by means of laser diffractoscopy.

Methods: Blood samples from healthy control subjects (n = 10) and Type I diabetic patients (n = 15) completely deficient of C-peptide were analysed at shear stresses ranging from 0.3 to 30 Pa.

Results: Erythrocyte deformability was lower in the group of Type I diabetic patients than in the control subjects. Preincubation of the diabetic blood samples with various concentrations of human proinsulin C-peptide for 8 h restored the deformability of erythrocytes, almost reaching the values of control samples. In contrast, proinsulin C-peptide did not modify the erythrocyte deformability of control subjects.

Conclusion/interpretation: We conclude that proinsulin C-peptide is able to ameliorate the impaired deformability of erythrocytes in Type I diabetic patients and we hypothesise that this effect is mediated by restoration of Na(+)-K(+)-ATPase activity, which is known to be attenuated in diabetic patients.

MeSH terms

  • C-Peptide / pharmacology*
  • Diabetes Mellitus, Type 1 / blood*
  • Enzyme Inhibitors / pharmacology
  • Erythrocyte Deformability / drug effects*
  • Erythrocytes / drug effects
  • Erythrocytes / enzymology
  • Humans
  • Lasers
  • Ouabain / pharmacology
  • Sodium-Potassium-Exchanging ATPase / antagonists & inhibitors

Substances

  • C-Peptide
  • Enzyme Inhibitors
  • Ouabain
  • Sodium-Potassium-Exchanging ATPase